Implementing intensity modulated radiotherapy to the prostate bed: Dosimetric study and early clinical results

Medical Dosimetry

Volumn 38, Issue 2, 2013, Pages 117-121

  Riou, Olivier ^a   Laliberté, Benoit ^b   Azria, David ^a   Menkarios, Cathy ^b   Llacer Moscardo, Carmen ^a   Dubois, Jean Bernard ^a   Aillères, Norbert ^a   Fenoglietto, Pascal ^a  

^a CENTRE VAL D AURELLE   (France)

^b MAISONNEUVE ROSEMONT HOSPITAL   (Canada)

Author keywords

Conformal radiotherapy; Intensity modulated radiotherapy; Postoperative; Prostate cancer; Toxicity

Indexed keywords

GONADORELIN AGONIST;

ACUTE TOXICITY; ADULT; AGED; ANATOMICAL VARIATION; ARTICLE; BLADDER; BLADDER IRRITATION; CHRONIC TOXICITY; CLINICAL ARTICLE; COMPUTER ASSISTED RADIOTHERAPY; DOSIMETRY; DYSURIA; FEASIBILITY STUDY; FEMUR HEAD; HIGH RISK PATIENT; HUMAN; INTENSITY MODULATED RADIATION THERAPY; MALE; NOCTURIA; POLLAKISURIA; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; RADIATION DOSE; RECTUM; RECTUM HEMORRHAGE; TREATMENT OUTCOME;

AGED; HUMANS; MALE; MIDDLE AGED; PILOT PROJECTS; PROSTATIC NEOPLASMS; RADIOMETRY; RADIOTHERAPY DOSAGE; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED; RADIOTHERAPY, ADJUVANT; RADIOTHERAPY, CONFORMAL; SALVAGE THERAPY; TREATMENT OUTCOME;

EID: 84876965183     PISSN: 09583947     EISSN: 18734022     Source Type: Journal    
DOI: 10.1016/j.meddos.2012.09.001     Document Type: Article

References (29)

1. Stephenson A.J., Scardino P.T., Kattan M.W., et al. Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. J. Clin. Oncol 2007, 25:2035-2041.
2. Stephenson A.J., Shariat S.F., Zelefsky M.J., et al. Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy. J. Am. Med. Assoc 2004, 291:1325-1332.
3. Katz M.S., Zelefsky M.J., Venkatraman E.S., et al. Predictors of biochemical outcome with salvage conformal radiotherapy after radical prostatectomy for prostate cancer. J. Clin. Oncol 2003, 21:483-489.
4. Bolla M., van Poppel H., Collette L., et al. Postoperative radiotherapy after radical prostatectomy: A randomised controlled trial (EORTC trial 22911). Lancet 2005, 366:572-578.
5. Wiegel T., Bottke D., Steiner U., et al. Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95. J. Clin. Oncol 2009, 27:2924-2930.
6. Thompson I.M., Tangen C.M., Paradelo J., et al. Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial. J. Am. Med. Assoc 2006, 296:2329-2335.
7. Thompson I.M., Tangen C.M., Paradelo J., et al. Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial. J. Urol 2009, 181:956-962.
8. Zelefsky M.J., Fuks Z., Hunt M., et al. High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer. J. Urol 2001, 166:876-881.
9. Aillères N., Azria D., Thézenas S., et al. Pilot study of conformal intensity modulated radiation therapy for localized prostate cancer. Cancer Radiother 2004, 8:59-69.
10. De Meerleer G.O., Fonteyne V.H., Vakaet L., et al. Intensity-modulated radiation therapy for prostate cancer: Late morbidity and results on biochemical control. Radiother. Oncol 2007, 82:160-166.
11. Zelefsky M.J., Chan H., Hunt M., et al. Long-term outcome of high dose intensity modulated radiation therapy for patients with clinically localized prostate cancer. J. Urol 2006, 176:1415-1419.
12. Sidhom M.A., Kneebone A.B., Lehman M., et al. Post-prostatectomy radiation therapy: Consensus guidelines of the Australian and New Zealand Radiation Oncology Genito-Urinary Group. Radiother. Oncol 2008, 88:10-19.
13. Michalski J.M., Lawton C., El Naga I., et al. Development of RTOG consensus guidelines for the definition of the clinical target volume for conformal postoperative radiation therapy for prostate cancer. Int. J. Radiat. Oncol. Biol. Phys 2010, 76:361-368.
14. Poortmans P., Bossi A., Vandeputte K., et al. Guidelines for target volume definition in post-operative radiotherapy for prostate cancer, on behalf of the EORTC Radiation Oncology Group. Radiother. Oncol 2007, 84:121-127.
15. Sohayda C., Kupelian P.A., Levin H.S., et al. Extent of extracapsular extension in localized prostate cancer. Urology 2000, 55:382-386.
16. Davis J.B., Reiner B., Dusserre A., et al. Quality assurance of the EORTC trial 22911. A phase III study of post-operative external radiotherapy in pathological stage T3N0 prostatic carcinoma: The dummy run. Radiother. Oncol 2002, 64:65-73.
17. Bastasch M.D., Teh B.S., Mai W., et al. Post-nerve-sparing prostatectomy, dose-escalated intensity-modulated radiotherapy: Effect on erectile function. Int. J. Radiat. Oncol. Biol. Phys 2002, 54:101-106.
18. Teh B.S., Mai W.Y., Augspurger M.E., et al. Intensity modulated radiation therapy (IMRT) following prostatectomy: more favorable acute genitourinary toxicity profile compared to primary IMRT for prostate cancer. Int. J. Radiat. Oncol. Biol. Phys 2001, 49:465-472.
19. Chen M.J., Weltman E., Hanriot R.M., et al. Intensity modulated radiotherapy for localized prostate cancer: Rigid compliance to dose-volume constraints as a warranty of acceptable toxicity?. Radiat. Oncol 2007, 2:6.
20. Nath S.K., Sandhu A.P., Rose B.S., et al. Toxicity analysis of postoperative image-guided intensity-modulated radiotherapy for prostate cancer. Int. J. Radiat. Oncol. Biol. Phys 2010, 78(Suppl 2):435-441.
21. Demeerleer G., Fonteyne V., Meersschout S., et al. Salvage intensity-modulated radiotherapy for rising PSA after radical prostatectomy. Radiother. Oncol 2008, 89:205-213.
22. Ost P., Fonteyne V., Villeirs G., et al. Adjuvant high-dose intensity-modulated radiotherapy after radical prostatectomy for prostate cancer: Clinical results in 104 patients. Eur. Urol 2009, 56:669-675.
23. Ost P., De Troyer B., Fonteyne V., et al. A matched control analysis of adjuvant and salvage high-dose postoperative intensity-modulated radiotherapy for prostate cancer. Int. J. Radiat. Oncol. Biol. Phys 2011, 80(Suppl 5):1316-1322.
24. Ost P., Lumen N., Goessaert A.S., et al. High-dose salvage intensity-modulated radiotherapy with or without androgen deprivation after radical prostatectomy for rising or persisting prostate-specific antigen: 5-Year results. Eur. Urol 2011, 60:842-849.
25. Menkarios C., Azria D., Laliberté B., et al. Optimal organ-sparing intensity-modulated radiation therapy (IMRT) regimen for the treatment of locally advanced anal canal carcinoma: A comparison of conventional and IMRT plans. Radiat. Oncol 2007, 2:41.
26. Guerrero M., Li X.A., Ma L., et al. Simultaneous integrated intensity-modulated radiotherapy boost for locally advanced gynecological cancer: Radiobiological and dosimetric considerations. Int. J. Radiat. Oncol. Biol. Phys 2005, 62:933-939.
27. Fenoglietto P., Laliberte B., Allaw A., et al. Persistently better treatment planning results of intensity-modulated (IMRT) over conformal radiotherapy (3D-CRT) in prostate cancer patients with significant variation of clinical target volume and/or organs-at-risk. Radiother. Oncol 2008, 88:77-87.
28. Digesú C., Cilla S., De Gaetano A., et al. Postoperative intensity modulated radiation therapy in high risk prostate cancer: A dosimetric comparison. Med. Dosim 2011, 36(Suppl 3):231-239.
29. Koontz B.F., Das S., Temple K., et al. Dosimetric and radiobiologic comparison of 3D conformal versus intensity modulated planning techniques for prostate bed radiotherapy. Med. Dosim 2009, 34:256-260.